What will the sales price of deuterated colexitinib be in 2025?

Deucravacitinib is an oral tyrosine kinase 2 (TYK2) selective inhibitor, mainly used in the treatment of moderate to severe plaque psoriasis. Many patients will be concerned about a question during the medication process: Since the drug is a tool for long-term disease control, does it mean that once it is started, it cannot be stopped? The answer is not absolute, but needs to be determined based on the individual condition, disease control level and the doctor's comprehensive assessment.

Psoriasis is a chronic, immune-mediated inflammatory skin disease characterized by recurrent and long-lasting attacks. Deuterated coxitinib inhibits the TYK2 signaling pathway and blocks the activation of key inflammatory factors such as IL-23, IL-12 and type I interferon, thereby improving skin lesions and symptoms. This mechanism of action cannot completely eliminate the root cause of the disease, so there is still a risk of disease recurrence after stopping the drug. Clinical observation shows that when the patient's symptoms are well controlled, if the drug is stopped suddenly, the skin lesions may gradually worsen or even rebound. This is why many experts recommend long-term maintenance treatment.

However, the so-called "cannot stop taking medication" is not an absolute prohibition. When the condition of some patients is under stable control and the doctor assesses that the skin lesion area and severity index have dropped significantly, they can try to discontinue the medication or extend the medication interval according to the specific circumstances. This usually requires comprehensive judgment based on imaging evaluation, inflammation indicators and patient quality of life, rather than blindly stopping on your own.

On the other hand, if intolerance, adverse reactions, or drug conflicts occur during long-term medication, it may be necessary to suspend or change other regimens under the guidance of a doctor. Therefore, whether to discontinue medication is not a one-size-fits-all decision, but requires a balance between risks and benefits.

Reference materials:https://go.drugbank.com/drugs/DB16650